Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genes predict response of adult leukemia patients to chemotherapy

22.03.2004


Genes can indicate which adult leukemia patients will respond to therapy and what the duration of their remission will be, according to a new study published in the April 1, 2004, issue of Blood, the official journal of the American Society of Hematology.



Researchers from the Dana-Farber Cancer Institute in Boston, Mass., and the University "La Sapienza" in Rome studied 33 patients that had all been recently diagnosed with adult T-cell acute lymphocytic leukemia (T-ALL), a type of cancer in which the body makes too many T lymphocytes.

"The present study investigates, for the first time, the identification of gene expression profiles associated with both short-term and long-term outcome in adult patients with T-ALL. While approximately 70 percent of pediatric patients with T-ALL have excellent long-term response to intensive chemotherapy, adult patients have a much less favorable outcome. Previously, this poor prognosis of adult T-ALL patients had not been attributed to specific genetic signatures," according to Jerome Ritz, M.D., of the Dana-Farber Cancer Institute, co-senior author of the study. Robin Foa, M.D., from the University "La Sapienza," also served as senior author.


Using microarray technology, a technique that can evaluate the expression of thousands of genes at once, researchers were able to compare the gene expression profiles of the patients who responded to chemotherapy to those who did not. Through gene expression profiling – a determination of which genes in a cell or group of cells are active – the scientists identified a single gene, IL-8, that was highly expressed in T-ALL cells that were resistant to treatment. Researchers also discovered a set of 30 genes that were highly expressed in leukemic cells from patients who achieved complete remission.

A model based on the expression of three genes – AHNAK, TTK, and CD2 – was also found to be highly predictive of the duration of remission, correctly classifying 71 percent of outcomes. The model was later verified by T-ALL samples taken from a separate group of 18 patients. Two conventional measures for predicting a patient’s outcome – the white blood cell count and the degree of differentiation (a comparison of the similarity between cancerous cells and their normal counterparts) – were also examined and appeared to be less predictive than the three-gene expression model.

The results of the study may help doctors customize a T-ALL patient’s treatment plan based on the individual’s predicted response to therapy using these methods. Further exploration of these genes may also lead to new therapeutic targets for adult T-ALL.

According to Donald Miller, M.D., Ph.D., Professor in the Division of Hematology at the University of Louisville and Director of the James Graham Brown Cancer Center in Louisville, Ky., "This work represents one of the first applications of genomics to an important clinical problem. It provides strong evidence that genetic analysis will help us provide better care to patients with leukemia and other malignant diseases."



This work was supported by the National Institutes of Health grant CA66996, the Ted and Eileen Pasquarello Research Fund, the Associazione Italiana per la Ricerca sul Cancro, the Instituto Superiore di Sanita, the Ministero dell’Istruzione, dell’Universita e della Ricerca Scientifica (MIUR), the Progetto FIRB, and the Associazione per le Leucemie Acute dell’adulto "Cristina Bassi" e Fondazione Cassa di Risparmio di Genova e Imperia.

Aislinn Raedy | EurekAlert!
Further information:
http://www.hematology.org/
http://www.bloodjournal.org

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>